Linked Life Data

17591837

Source:http://linkedlifedata.com/resource/pubmed/id/17591837

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2007-6-26
pubmed:abstractText
Anthracyclines are among the most effective drugs for patients with breast cancer. Their use, however, has been limited by associated toxic effects, including myelosuppression, alopecia, nausea and vomiting, stomatitis, and most importantly, cardiotoxicity. Liposomal anthracyclines were developed to increase the therapeutic index of conventional anthracyclines by maintaining antitumor efficacy while improving the safety profile. There are currently two liposomal formulations available for treatment of advanced disease: a not pegylated liposomal doxorubicin and a pegylated liposomal doxorubicin. This review will focus on both liposomal formulations of doxorubicin which are approved in Europe and Canada for use in patients with metastatic breast cancer.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
0923-7534
pubmed:author
pubmed:issnType
Print
pubmed:volume
18 Suppl 6
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
vi70-3
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Role of liposomal anthracyclines in breast cancer.
pubmed:affiliation
Medical Oncology Unit, Vito Fazzi Hospital, Lecce. vitolorusso@inwind.it
pubmed:publicationType
Journal Article, Comparative Study, Review